scholarly journals VITAMIN D AND PNEUMONIA

2018 ◽  
Vol 25 (04) ◽  
pp. 532-537
Author(s):  
Muhammad Shamaoon ◽  
Dr Maryam ◽  
Muhammad Ahsan ◽  
Rahman Ahmad
Keyword(s):  
Vitamin D ◽  
Controlled Trial ◽  
Intervention Group ◽  
Vitamin D Supplementation ◽  
Hospital Treatment ◽  
Randomized Controlled ◽  
Inflammatory Conditions ◽  
Group A ◽  
Group B

Background: Pneumonia is lower respiratory tract infection (LRTI) andrepresents inflammatory conditions of the lungs i.e of the lower respiratory tracts, air sacs andlung parenchyma.1 Objectives: To determine the role of vitamin D supplementation in reducingmorbidity in children with pneumonia. Study Design: Randomized Controlled trial. Place andDuration of Study: Pediatric Department, Mayo Hospital Lahore from December 2014 to May2015. Patient & Methods: Two hundred children of age 2 – 59 months with pneumonia (fever,cough, tachypnea, and subcostal recessions) and low vitamin D level (< 20 ng/ml) were includedin the study. One Hundred pneumonia patients received antibiotics (group A) and vitamins D(100,000 IU) while another group of hundred patients received only antibiotics without vitaminsupplementation (group B). When respiratory distress settled, length of stay in hospital wascalculated at the time of discharged. All patients were followed in pediatric OPDs for 3 monthsafter in-hospital treatment to pick recurrence of pneumonia symptoms (if any). Results: Themean recovery time for vitamin D group (5.7 +2.8 days) and non-vitamin D (6.1+2.8 days)was almost same with P=0.29. But the frequency of repeated episodes of pneumonia within30 days of treatment was lower in intervention group n=4 (2%) than the non-intervention groupn=18 (9%) (P = 0.002). Conclusion: 100,000 IU of vitamin D given once during treatment ofpneumonia decreases the chances of recurrence in the next 30 days.

scholarly journals The role of glucomannan fiber in childhood functional constipation

2016 ◽  
Vol 56 (2) ◽  
pp. 95
Author(s):  
Indiana Aulia ◽  
Supriatmo Supriatmo ◽  
Emil Azlin ◽  
Atan Baas Sinuhaji
Keyword(s):  
Controlled Trial ◽  
Functional Constipation ◽  
Boarding School ◽  
Chi Square ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Rome Iii ◽  
Group A ◽  
Group B

its most common type is functional constipation. The dietary fiber may be useful in childhood functional constipation management, but unfortunately the role of fiber in functional constipation is still less developed.Objective To determine the role of glucomannan in treatment of childhood functional constipation.Methods A crossover randomized controlled trial (RCT) was done from May until July 2012 in a boarding school in Medan, North Sumatera. The subjects were children with functional constipation aged 7 to 12 years. Subjects were randomised into two group receiving glucomannan fiber as polysaccharide gel (group A) and maltodextrin as placebo (group B) with each dose of 100 mg/kg/day (maximum of 5 g/day) diluted in 50 ml water/500 mg for 4 weeks, then after a wash out period we did the crossover of the two groups. Frequency and consistency of stools were recorded into diary sheet for 4 and 8 weeks of treatment. Functional constipation has been diagnosed based on Rome III criteria. Data was analyzed using independent T-test and Chi-square test.Results A total of 36 subjects were eligible with each group consisting of 18 subjects and mean of weight of 25 kg. We found significant difference in stool frequency, treated on glucomannan with P= 0.002 before and P = 0.0001 after the wash out period. For stool consistency, we found difference while treated on glucomannan 9/18 (P= 0.034) in 4 weeks before and 11/18 (P = 0.008) in 4 weeks after the wash out period.Conclusion Glucomannan has significant effect to improve functional constipation especially in 4 weeks treatment.

scholarly journals Vitamin D Supplementation during Pregnancy- A Double Blinded Randomized, Controlled, Dose-Comparison, Trial in Pakistan

2020 ◽  
Author(s):  
Sidrah Nausheen ◽  
Lumaan Shaikh ◽  
Atif Habib ◽  
Farhana Tabassum ◽  
Arjumand Rizvi ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Vitamin D Supplementation ◽  
Control Group ◽  
Randomized Controlled ◽  
Dose Comparison ◽  
Group A ◽  
Comparison Trial ◽  
Group B ◽  
Double Blinded

Abstract Vitamin D deficiency during pregnancy is a public health problem in Pakistan, and prevalent among most women of reproductive age in the country. Vitamin D supplementation during pregnancy is suggested to prevent adverse pregnancy outcomes and prevent vitamin D deficiency in both the mother and her newborn. However, there remains uncertainty surrounding the appropriate and safe dose for vitamin D supplementation in pregnant women who experience deficiency. We conducted a double-blinded, randomized, controlled, dose-comparison trial aimed to evaluate the relationship between different doses of vitamin D supplementation during pregnancy and pregnancy outcomes among women in a maternity hospital of the Aga Khan University (AKU) in Karachi, Pakistan. Pregnant women (n=350) in their first trimester were recruited and randomized to three treatment groups of vitamin D supplementation: 4,000 IU/day (Group A; n=120), 2,000 IU/day (Group B; n=115), or 400 IU/day (Group C – control; n=115). Deficiency in serum vitamin D (serum 25OHD <20ng/mL) at baseline was prevalent in more than 95% of women in each group. Participants in group A had the lowest vitamin D deficiency at endline and in newborns (endline: 75.9%; neonatal: 64.9%), followed by group B (endline: 84.9%; neonatal: 73.7%) and then the control group (endline: 90.2%; neonatal: 91.8%). Vitamin D deficiency was significantly lower in group A than group C (p=0.006) for women at endline, and lower in both group A and group B than the control group (p=0.001) in neonates. There were no adverse events attributable to vitamin D supplementation in all groups. Our study concluded that vitamin D supplementation with 4000 IU/day is safe and effective in reducing the risk of maternal and neonatal vitamin D deficiency.

scholarly journals A Randomized, Controlled Trial of Vitamin D Supplementation upon Musculoskeletal Health in Postmenarchal Females

2010 ◽  
Vol 95 (10) ◽  
pp. 4643-4651 ◽  
Author(s):  
K. A. Ward ◽  
G. Das ◽  
S. A. Roberts ◽  
J. L. Berry ◽  
J. E. Adams ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Quantitative Computed Tomography ◽  
Intervention Group ◽  
Vitamin D Supplementation ◽  
Vitamin D2 ◽  
Double Blind ◽  
Randomized Controlled ◽  
Jump Velocity

Context: There has been a resurgence of vitamin D deficiency rickets throughout the developed world, with infants and adolescents being primarily affected. Adolescence is a crucial period for muscle and bone mineral accumulation. Objective: The aim was to determine the effect of vitamin D supplementation on the adolescent musculoskeletal system. Design and Setting: We conducted a community-based, double-blind, randomized controlled trial in a secondary school. Participants: Postmenarchal 12- to 14-yr-old females participated in the trial. Ninety-nine were screened, 73 were included in randomized controlled trial, and 69 completed the trial. There were no adverse events. Intervention: Four doses of 150,000 IU vitamin D2 (ergocalciferol) were given over 1 yr. Main Outcome Measures: Dual-energy x-ray absorptiometry, peripheral quantitative computed tomography, and jumping mechanography were used. Results: At follow-up, 25-hydroxyvitamin D [25(OH)D] status was 56.0 ± 8.9 nmol/liter in the intervention group and 15.8 ± 6.6 nmol/liter in controls. There were no effects of supplementation on bone; however, for muscle function, efficiency of movement improved in the vitamin D-treated group. There was an interaction between baseline 25(OH)D concentration and response to vitamin D supplementation for muscle jump velocity. Conclusions: Despite improvements in 25(OH)D status, treatment with vitamin D2 was not shown to increase mineral accretion, bone geometry or strength, muscle force, or power. There were greater increases in jump velocity in girls with the lowest baseline 25(OH)D concentrations. Lack of effect of intervention after the period of peak mineral and muscle mass accretion suggests that earlier action is required.

scholarly journals Effect of vitamin D supplementation, directly or via breast milk for term infants, on serum 25 hydroxyvitamin D and related biochemistry, and propensity to infection: a randomised placebo-controlled trial

2016 ◽  
Vol 116 (1) ◽  
pp. 52-58 ◽  
Author(s):  
David D. Chandy ◽  
Jahnavi Kare ◽  
Shakal N. Singh ◽  
Anjoo Agarwal ◽  
Vinita Das ◽  
...  
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Controlled Trial ◽  
Sun Exposure ◽  
Vitamin D Supplementation ◽  
Elevated Alkaline Phosphatase ◽  
Hydroxyvitamin D ◽  
Group A ◽  
25 Hydroxyvitamin D ◽  
Group B

AbstractWe assessed the effect of vitamin D supplementation on related biochemistry, infection and dentition of the infant. In a double-blind, placebo-controlled trial conducted in Lucknow, India (latitude 26°N), 230 mother –newborn pairs were randomised to receive, for 9 months, 3000µg/month oral vitamin D3 by the mother (group A) or 10µg/d by the infant (group B) or double placebo (group C). All babies received 15 min of sun exposure (unclothed) during massage. Infants’ median 25-hydroxyvitamin D (25(OH)D) was lower in group C (median 45·3; interquartile range (IQR) 22–59·5 nmol/l) than in groups A (median 60·8; IQR 41·3–80·5 nmol/l (P<0·01)) and B (median 61·3; IQR 41·3–75·3 nmol/l (P<0·05)) at 3·5 months. Infant 25(OH)D correlated negatively with infant parathyroid hormone (r −0·46, P<0·01). Elevated alkaline phosphatase (>7.5µkat/l) was significantly more frequent in group C babies (16 %) than in group A (4 %) or group B (0 %) babies. The number of days with respiratory or diarrhoeal infection by 9 months of age was higher in group C (median 46·5; IQR 14·8–73·3 d) than in group A (median 18·5; IQR 8·8–31·0 d (P<0·01)) or group B (median 13·0; IQR 7·0–28·5 (P<0·05)). We conclude that monthly maternal or daily infant supplementation with vitamin D along with sun exposure is superior to sun exposure alone in maintaining normal infant 25(OH)D at 3·5 months, and provide protection from elevated alkaline phosphatase and infectious morbidity.

scholarly journals A prospective analysis of vitamin D and recurrent benign paroxysmal positional vertigo

2019 ◽  
Vol 5 (6) ◽  
pp. 1548
Author(s):  
N. Gopinathan Pillai ◽  
Induvarsha Gopinath
Keyword(s):  
Vitamin D ◽  
Benign Paroxysmal Positional Vertigo ◽  
Vitamin D Supplementation ◽  
Vitamin Deficiencies ◽  
Positional Vertigo ◽  
Group A ◽  
Vitamin D Supplements ◽  
Group B ◽  
Paroxysmal Positional Vertigo

<p><strong>Background:</strong> The aim of the present study was to prospectively evaluate the role of vitamin D in the recurrence of Benign paroxysmal positional vertigo (BPPV). The BPPV is one of the commonest causes for peripheral vertigo. Many studies stated that BPPV can be associated with many co-morbidities and vitamin deficiencies.</p><p class="abstract"><strong>Methods:</strong> In our study, we prospectively conducted an observational study in patients suffering from BPPV, from a study period of June 2015 to June 2018, to evaluate the role of vitamin D and calcium in those patients.</p><p class="abstract"><strong>Results:</strong> Three forty eight patients between the age group of 40 to 82 years, suffering from BPPV were included in the study. It includes 235 females and 113 male patients. Out of these 108 patients had noticed vitamin D deficiency and were randomly divided into 2 groups in which group A received Vitamin D supplementation and Group B did not received vitamin D supplements. Calcium levels were found to be less in 15 patients between 7 and 10.5 mg/dl, however a larger sample is required for its correlation. All patients were followed up for 1 year.</p><p class="abstract"><strong>Conclusions:</strong> The study showed a significant decrease of BPPV in those who received vitamin D supplementation.</p>

scholarly journals Utility of Gastric Lavage in Vigorous Neonates Delivered with Meconium Stained Liquor: A Randomized Controlled Trial

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Jatin Garg ◽  
Rupesh Masand ◽  
Balvir Singh Tomar
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Tertiary Care ◽  
Gastric Lavage ◽  
Secondary Outcome ◽  
Randomized Controlled ◽  
Group A ◽  
Feed Intolerance ◽  
Group B

Objective. To determine the incidence of feed intolerance in vigorous babies with meconium stained liquor (MSL) who received prophylactic gastric lavage as compared to those who were not subjected to this procedure.Design. Randomized controlled trial.Setting. Tertiary care teaching hospital.Participants/Intervention. 330 vigorous babies delivered with MSL and satisfying the predefined inclusion criteria were randomized either to receive gastric lavage (group A,n=165) or to not receive gastric lavage (group B,n=153). Clinical monitoring was subsequently performed and recorded in prestructured proforma.Results. There was no significant statistical difference (P>0.05) in incidence of feed intolerance in “lavage” and “no lavage” groups.Secondary Outcome. There was no evidence of secondary respiratory distress in either group. None of the patients in the lavage group exhibited adverse effects owing to the procedure.Conclusions. There is no role of prophylactic gastric lavage in neonates born with MSL.

scholarly journals HEPATOTOXICITY;

2017 ◽  
Vol 24 (08) ◽  
pp. 1200-1205
Author(s):  
Aamna Khokhar ◽  
Aisha Qayyum ◽  
Momina Khokhar
Keyword(s):  
Controlled Trial ◽  
Protective Role ◽  
Alanine Transaminase ◽  
Blood Samples ◽  
Medical College ◽  
Randomized Controlled ◽  
Group A ◽  
Group B ◽  
Group D

Objectives: To evaluate the protective role of silymarin against methotrexate(MTX) induced hepatotoxicity in mice. Study design: Randomized controlled trial on animalmodel. Period: 06 months from March 2016 to August 2016. Settings: Department ofPharmacology and Therapeutics, Army Medical College, Rawalpindi. Material and Methods:Thirty male BALB/c mice were randomly divided into five groups (n=6). Group A received 0.2 mlnormal saline intraperitoneally served as control for MTX. Group B received 0.2 ml distilled waterorally for 7 days served as control for oral silymarin. Group C received single intraperitonealinjection of MTX 20 mg/kg. Group D received silymarin 25 mg/kg orally for seven days. GroupE received silymarin 25 mg/kg orally for 7 days with MTX 20 mg/kg intraperitoneally at day 4.Blood samples for measuring serum ALT (Alanine Transaminase), AST (Aspartate transaminase)and ALP (Alkaline Phosphatase) along with liver samples for hepatic histological examinationwere taken after 24 hours of last dose. Results: Silymarin show hepatoprotective effect againstMTX induced hepatotoxicity. Conclusion: Silymarin has hepatoprotective potential whenadministered along with MTX.

Sign in / Sign up

Export Citation Format

Share Document